Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.

Autor: Robak T; Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland., Hellmann A; Department of Hematology, Medical University of Gdansk, Gdansk, Poland., Kloczko J; Department of Haematology, Medical University of Bialystok, Bialystok, Poland., Loscertales J; Haematology, Hospital Universitario La Princesa, IIS-IP Madrid, Spain., Lech-Maranda E; Department of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland.; Department of Haematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland., Pagel JM; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA., Mato A; Center for CLL, University of Pennsylvania and Hackensack University, Philadelphia, PA, USA., Byrd JC; Division of Hematology, The Ohio State University, Columbus, OH, USA., Awan FT; Division of Hematology, The Ohio State University, Columbus, OH, USA., Hebart H; Department of Haematology/Oncology, Stauferklinikum Schwaebisch Gmuend, Mutlangen, Germany., Garcia-Marco JA; Hospital U. Puerta de Hierro-Majadahonda, Madrid, Spain., Hill BT; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Hallek M; Department I of Internal Medicine, Centre of Integrated Oncology Koln and Cluster of Excellence on Cellular Stress Responses in Aging (CECAD) University of Cologne, Cologne, Germany.; German CLL Study Group., Eisenfeld AJ; Aptevo Therapeutics, Seattle, WA, USA., Stromatt SC; Aptevo Therapeutics, Seattle, WA, USA., Jaeger U; German CLL Study Group.; Department of Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria.

Publikováno v: British journal of haematology [Br J Haematol] 2017 Feb; Vol. 176 (4), pp. 618-628. Date of Electronic Publication: 2016 Dec 15.

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Autor: Gopal AK; Department of Medicine, University of Washington, Box 358081, 825 Eastlake Ave E.,, MS G3200, Seattle, WA, USA, agopal@u.washington.edu., Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A

Publikováno v: Investigational new drugs [Invest New Drugs] 2014 Dec; Vol. 32 (6), pp. 1213-25. Date of Electronic Publication: 2014 Jun 15.

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

Autor: O'Brien ME; Royal Marsden Hospital, London, United Kingdom., Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2008 Jul; Vol. 3 (7), pp. 728-34.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.

Autor: Paz-Ares L; Hospital Universitario 12 de Octubre, Servicio de Oncología Médica, Madrid 28041, Spain., Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P

Publikováno v: British journal of cancer [Br J Cancer] 2008 May 20; Vol. 98 (10), pp. 1608-13. Date of Electronic Publication: 2008 May 13.